Fresh from the sale of their former start-up, device entrepreneurs Chas Taylor and Paul Gilson were contemplating their next venture when they ran into a vascular surgeon of their acquaintance. The surgeon had a particular clinical issue with a widely used device – the inferior vena cava (IVC) filters used to capture blood clots in the bloodstream before they become potentially lethal pulmonary embolisms.
The surgeon had implanted temporary IVC filters in a whole series of patients, in particular, trauma patients, but those filters...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?